

## Collaborative Clinical, Cross-Discipline Team Leader, and Division Summary Review

<b>Date</b>	See Electronic Stamp Date
<b>From</b>	Juwaria Waheed, MD, Clinical Reviewer Anil Rajpal, MD, MPH, CDTL Nikolay Nikolov, MD, Division Director
<b>Subject</b>	Collaborative Clinical, Cross-Discipline Team Leader, and Division Summary Review
<b>sBLA # and Supplement#</b>	761118/S-006
<b>Applicant</b>	Pfizer, Inc.
<b>Date of Submission</b>	October 7, 2021
<b>BsUFA Goal Date</b>	August 7, 2022
<b>Proprietary Name (Proper Name)</b>	Abrilada (adalimumab-afzb)
<b>Product Code Name</b>	PF-06410293
<b>Reference Product Proprietary Name (Proper Name)</b>	Humira
<b>Dosage Form(s)</b>	No new proposed dosage forms
<b>Applicant Proposed Indication(s)/Population(s)</b>	Polyarticular Juvenile Idiopathic Arthritis (pJIA) 2-4 years of age Pediatric Crohn's disease (CD) 6 years of age and older
<b>Applicant Proposed Dosing Regimen(s)</b>	Same as US-Humira dosing for the respective indications
<b>Recommendation on Regulatory Action</b>	<i>Approval</i>
<b>Recommended Indication(s)/Population(s) (if applicable)</b>	Polyarticular Juvenile Idiopathic Arthritis (pJIA) 2 years of age and older Pediatric Crohn's disease (CD) 6 years of age and older
<b>Recommended Dosing Regimen(s) (if applicable)</b>	Same as US-Humira dosing for the respective indications

### 1. Introduction

The Applicant submitted this supplement 006 to expand the indications of Juvenile Idiopathic Arthritis (JIA) and Crohn's Disease (CD) that were previously under orphan exclusivity and to provide the pediatric assessment for Ulcerative Colitis (UC). In doing so, the Applicant also proposes to fulfill the PREA PMR commitments that were issued with the original approval of Abrilada on November 15, 2019 (See Section 9, Pediatrics). No new clinical information is included in this submission. Rather, the Applicant cross-references the original application submission under BLA 761118 and has now provided supporting justification of extrapolation for each of the indications currently being sought for licensure.

## 2. Background

Adalimumab-afzb (Abilada) is a biosimilar to US-licensed Humira (US-Humira) approved on November 15, 2019 under section 351(k) of the Public Health Service Act (PHS Act) for the treatment of:

- 1) Rheumatoid Arthritis (RA)
- 2) Juvenile Idiopathic Arthritis (JIA) in patients 4 years of age and older
- 3) Psoriatic Arthritis (PsA)
- 4) Ankylosing Spondylitis (AS)
- 5) Adult Crohn's Disease (adult CD)
- 6) Ulcerative Colitis (UC)
- 7) Plaque Psoriasis (PsO)

The Applicant originally submitted a BLA under section 351(k) of the Public Health Service Act (PHS Act) for adalimumab-afzb on November 16, 2018.

The original application included the following:

- A comprehensive comparative analytical assessment of adalimumab-afzb, US-Humira, and EU-approved Humira (EU-Humira). These included comparative characterization of physicochemical attributes and comparative functional assessments.
- Nonclinical studies including a one-month, repeat-dose general toxicology and TK study in cynomolgus monkeys to compare the effects of adalimumab-afzb to those of EU-Humira.
- A PK similarity study (B5381007) in healthy subjects following a single SC 40 mg dose of adalimumab-afzb, EU-Humira, or US-Humira.
- A comparative clinical study (B5381002) evaluating comparative efficacy, safety, and immunogenicity of adalimumab-afzb and EU-Humira in combination with methotrexate in patients with moderately to severely active RA who have had an inadequate response to methotrexate.
- A scientific justification (based on mechanism of action, PK, immunogenicity, and toxicity) for extrapolation of data and information submitted in the application to support licensure of adalimumab-afzb for each of the additional indications for which Pfizer was seeking licensure and for which US-Humira had been previously licensed.

In considering the totality of the evidence for the original BLA submission, review of the data submitted by the Applicant showed that adalimumab-afzb is highly similar to US-Humira, notwithstanding minor differences in clinically inactive components, and that there are no clinically meaningful differences between adalimumab-afzb and US-Humira in terms of the safety, purity, and potency of the product. The Applicant also provided adequate scientific justification for extrapolation of data and information to support licensure of adalimumab-afzb for the non-studied indications being sought. Review of the information submitted by the Applicant demonstrated that adalimumab-afzb is biosimilar to US-Humira for each of the following indications for which US-Humira has been previously approved and the Applicant was seeking licensure for adalimumab-afzb: RA, JIA in patients 4 years and older, PsA, AS, PsO,

Adult CD, and Adult UC. See DPARP BMER in collaboration with DDDP and DGIEP, dated November 15, 2019.<sup>1</sup>

### **3. Product Quality**

There are no CMC or product quality issues that would preclude approval of the indications sought for licensure.

### **4. Nonclinical Pharmacology/Toxicology**

There are no nonclinical pharmacology/toxicology issues that would preclude approval of the indications sought for licensure.

### **5. Clinical Pharmacology**

There are no clinical pharmacology issues that would preclude approval of the indications sought for licensure.

### **6. Clinical/Statistical- Efficacy**

Adalimumab-afzb was previously studied in patients with RA in the comparative clinical study (B5381002). The data were previously reviewed and summarized in the BMER dated November 15, 2019 for the original application. There are no clinical/statistical efficacy issues that would preclude approval of the indications sought for licensure.

### **7. Safety**

Adalimumab-afzb was previously studied in patients with RA in the comparative clinical study (B5381002) and in healthy subjects in comparative PK studies. The data were previously reviewed and summarized in the BMER dated November 15, 2019 for the original application. There are no clinical safety issues that would preclude approval of the indications sought for approval.

### **8. Considerations for Extrapolation of Biosimilarity in Other Conditions of Use**

The Guidance for Industry: Questions and Answers on Biosimilar Development and the Biologics Price Competition and Innovation (BPCI) Act<sup>2</sup> (September 2021), notes that in the context of the potential biosimilar product under the Act, the biosimilar applicant may fulfill Pediatric Research Equity Act (PREA) requirements by satisfying the statutory requirements for demonstrating

---

<sup>1</sup> DPARP: Division of Pulmonary, Allergy and Rheumatology Products; BMER: Biosimilar Multi-disciplinary Evaluation and Review; DDDP: Division of Dermatology and Dental Products; DGIEP: Division of Gastroenterology and Inborn Errors Products

<sup>2</sup> <https://www.fda.gov/media/119258/download>

biosimilarity and providing an adequate scientific justification under the Biologics Price Competition and Innovation (BPCI) Act for extrapolating data and information to support a licensure for each condition of use for which licensure is sought.<sup>3</sup>

Adalimumab-afzb is an approved biosimilar for the treatment of RA, PsA, AS, adult CD, adult UC, JIA in patients 4 years of age and older, and PsO. The Applicant has now submitted justification for extrapolation of the data and information in support of licensure of adalimumab-afzb for the treatment of pJIA in patients 2 years to less than 4 years of age, pediatric CD in patients 6 years to 17 years of age, and pediatric UC in patients 5 years to 17 years of age (see also Section 9 Pediatrics).

Scientific considerations for the extrapolation of biosimilarity to the pediatric populations - JIA (2-4 years), Pediatric CD (6-17 years), and Pediatric UC (5 -17 years), are outlined below:

1. Biosimilarity has previously been established between adalimumab-afzb and the reference product, US-Humira based on extensive analytical characterization, comparative PK studies, comparative clinical study, safety and immunogenicity data.
2. Adequate scientific justification supporting extrapolation of scientific information and data (based on mechanism of action, PK and immunogenicity, safety and toxicities) from the original BLA submission (761118) allowed licensure of non-studied indications for which the reference product has been approved.
3. Similar extrapolation of scientific information and data from the original application applies to the indications subject of this supplement. Therefore, in pJIA in patients 2 years to less than 4 years of age, pediatric CD in patients 6 years to 17 years of age, and pediatric UC in patients 5 years to 17 years of age:
  - a. a similar PK profile would be expected between adalimumab-afzb and US-Humira
  - b. similar immunogenicity would be expected between adalimumab-afzb and US-Humira
  - c. similar safety profile would be expected between adalimumab-afzb and US-Humira
  - d. Pfizer addressed each of the known and potential mechanisms of action of US-Humira and submitted data to support the conclusion that adalimumab-afzb and US-Humira have the same mechanisms for each of the discussed indications, to the extent that the mechanisms of action are known or can reasonably be determined

Additional considerations include:

Regarding MOA, the shared importance of TNF in the pathophysiology of disease, and clinical response, in adult RA and JIA support extrapolation to the existing JIA data for the reference product. There are no data or scientific evidence that the MOA differs in pJIA in patients between 2 years to less than 4 years of age such that the same justification for extrapolation could not apply to this younger subgroup of pJIA patients.

---

<sup>3</sup> For more information on extrapolation in this context, see FDA's guidance for industry Scientific Considerations in Demonstrating Biosimilarity to a Reference Product (May 2015)

In terms of MOAs for the IBD indications, including pediatric CD in patients 6 years of age and older and pediatric UC in patients 5 years of age and older, in addition to the neutralization of a soluble form of tumor necrosis factor alpha (sTNF), transmembrane tumor necrosis factor alpha (mTNF, also tmTNF) binding and subsequent reverse signaling and/or Fc-related effects are also relevant. However, there are no data or scientific evidence that the MOA differs in adult CD and adult UC such that the same justification for extrapolation could not apply to pediatric CD patients 6 years of age and older and to pediatric UC patients 5 years of age and older, respectively.

Regarding immunogenicity and PK, data supported extrapolation in the original application for pJIA in patients 4 years of age and older, adult CD, and adult UC. There is no data or scientific evidence that PK and immunogenicity differ in pJIA in patients between 2 years to less than 4 years of age such that the same justification for extrapolation could not apply. Similarly, there is no data or scientific evidence that PK and immunogenicity differ in pediatric CD patients 6 years of age and older, and pediatric UC patients 5 years of age and older such that the same justification for extrapolation could not apply.

In terms of safety and toxicity, the same safety data which supported approval of the extrapolated indications, including pJIA in patients 4 years of age and older, adult CD and adult UC, is applicable and relevant to support safety in patients with pJIA between 2 years to less than 4 years of age, pediatric CD in patients 6 years of age and older, and pediatric UC in patients 5 years of age and older.

Also see Division of Gastroenterology memo BLA 761118 S-006 in the Appendix for further discussion of the pediatric CD and pediatric UC indications.

In conclusion, the totality of evidence as discussed above is adequate to justify extrapolating all of the data and information submitted to the BLA to support biosimilarity for the indication of “reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older” and for the indication of “Crohn’s disease in pediatric patients 6 years of age and older.”

Note that while the Applicant has also submitted acceptable extrapolation justification for pediatric UC patients 5 years of age and older, FDA has determined that US-Humira is eligible for orphan drug exclusivity for pediatric UC, ages 5-17 years. FDA therefore cannot license adalimumab-afzb for this indication prior to the expiration of the orphan drug exclusivity on February 24, 2028.

This information is sufficient to also fulfill the requirements of PMR 3708-1, PMR 3708-2 and PMR 3708-3 from the approval of original BLA. To address PREA requirements for these indications and age-groups, the Applicant satisfies the statutory requirements by demonstrating biosimilarity and also provides an adequate scientific justification under the BPCI Act for extrapolating the pediatric information from the reference product to the biosimilar product.

## 9. Pediatrics

On November 15, 2019, adalimumab-afzb was approved by FDA as a biosimilar to US-Humira. It was considered to have a new active ingredient and triggered PREA. At that time, the PREA-required pediatric assessments for pediatric JIA patients 2 years to less than 4 years of age, pediatric CD patients 6 years to 17 years of age and pediatric UC in pediatric patients 5 years to 17 years of age were deferred.

The following PMRs were issued:

PMR #	PMR Details	Final Report Due Date
3708-1	Assessment of Abrilada (adalimumab-afzb) for the treatment of polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 to less than 4 years of age	September 2021
3708-2	Assessment of Abrilada (adalimumab-afzb) for the treatment of Pediatric Crohn's disease (CD) in pediatric patients 6 years to 17 years of age.	September 2021
3708-3	Assessment of Abrilada (adalimumab-afzb) for the treatment of pediatric ulcerative colitis (UC) in pediatric patients 5 years to 17 years of age	September 2021 (Extended from December 2020 by FDA)

In submissions dated June 3, 2021, the Applicant provided final reports to fulfill PMRs 3708-1, 3708-2, and 3708-3. The current supplement cross-references the pediatric assessments with justification for extrapolation proposing to fulfill the PREA PMRs (3708-1, 3708-2, and 3708-3) which was submitted to the BLA on June 3, 2021.

The Applicant has provided adequate information to fulfill the requirements of PMR 3708-1, PMR 3708-2 and PMR 3708-3 from the approval of original BLA. Refer to Section 8 Extrapolation for the review of the scientific assessment of these requirements.

A Pediatric Review Committee (PeRC) meeting occurred on May 24, 2022. The PeRC recommendation was the following: “The PeRC agrees that the PMR has been fulfilled for pJIA and CD, and the product will be labeled for pediatric use for these indications. However, labeling will not be updated for UC until 2028 when the exclusivity expires.”

## 10. Other Relevant Regulatory Issues

None.

## **11. Labeling**

The proposed Abrilada prescribing information incorporated relevant data and information from the US-Humira prescribing information, with appropriate modifications. It was determined that the proposed labeling is consistent with the current FDA labeling practice. The labeling has been agreed upon with the Applicant.

## **12. Postmarketing Recommendations**

There are no potential or new safety or efficacy issues determined from this review that warrant further assessment with a postmarketing requirements or commitments.

## **13. Risk Evaluation and Mitigation Strategies**

The review team did not identify a need for Risk Evaluation and Mitigation Strategies (REMS) to ensure the safe use of adalimumab-afzb.

## **14. Recommended Regulatory Action**

Approval.

## **15. DRTM Division Director/Signatory Comments**

I concur with the team's assessment of the data and information submitted in this supplemental BLA.

The information submitted fulfills PREA-required assessments for JIA in patients 2 to <4 years of age, pediatric Crohn's disease, and pediatric Ulcerative colitis (PMR 3708-1, PMR 3708-2, and PMR 3708-3, respectively, from the approval of original BLA 761118, November 15, 2019).

No additional data, new PMRs, PMCs, or REMS are required for this supplement.

## 16. Appendix

### Division of Gastroenterology Memo

Abrilada (PF-06410293) is currently approved for the treatment of inflammatory bowel disease (IBD) indications of Crohn's disease (CD) and ulcerative colitis (UC) in adults, in addition to other indications<sup>4</sup>. While the IBD indications were not directly studied in the PF-06410293 clinical program, as noted in the DG extrapolation review of the original BLA<sup>5</sup> dated 11/15/2019, consistent with the principles of the FDA Guidance For Industry, Scientific Considerations in Demonstrating Biosimilarity to a Reference Product<sup>6</sup>, the Applicant had provided sufficient scientific justification based on the mechanism of action, PK, immunogenicity and toxicity profile, and sufficient information, including clinical data from the studied populations (healthy subjects and patients with rheumatoid arthritis, RA), to support licensure of PF-06410293 for UC and CD in adults. At the time of the original BLA application, the Applicant did not seek the licensure of the pediatric CD indication due to pending orphan drug exclusivity. In addition, US-Humira was not licensed for the pediatric UC indication at the time. Thus, the approval letter for BLA 761118, dated 11/15/2019 included the following PREA PMRs to address the pediatric IBD indications:

3708-2 Assessment of Abrilada (adalimumab-afzb) for the treatment of pediatric Crohn's disease (CD) in pediatric patients 6 years to 17 years of age.

Final Report Submission: September 2021

3708-3 Assessment of Abrilada (adalimumab-afzb) for the treatment of pediatric Ulcerative colitis (UC) in pediatric patients 5 years to 17 years of age.

Final Report Submission: September 2021 (updated as per the deferral extension letter issued by the DG on 08/18/2020)

The orphan drug exclusivity of US-Humira for pediatric CD had since expired on September 23, 2021. Furthermore, on February 24, 2021, US-Humira was licensed for the treatment of moderately to severely active UC in pediatric patients 5 years and older, and eligible for an orphan drug exclusivity until February 24, 2028. With the submission of BLA 761118/S-006 (also cross-referencing the pediatric assessments submitted to the BLA on 06/03/2021), the Applicant intends to address the pending PREA PMRs for Abrilada for pediatric CD (3708-2) and pediatric UC (3708-3) and is seeking the licensure for the pediatric CD indication.

The Applicant has provided justification for extrapolating data and information submitted in the application and supplement to support licensure of PF-06410293 as a biosimilar for each of the pediatric IBD indications for which licensure is sought and for which US-Humira has been previously approved. The Applicant's justification was evaluated and considered adequate, as summarized below:

<sup>4</sup> Abrilada USPI accessed on 03/01/2022:

[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2019/761118s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761118s000lbl.pdf)

<sup>5</sup> Abrilada, Biosimilar Multi-disciplinary Evaluation and Review (BMER), Section 7.6.1., 11/15/2019

<sup>6</sup> Guidance for Industry, Scientific Considerations in Demonstrating Biosimilarity to a Reference Product (2015)

**Mechanism of Action (MOA)-** Similar to the studied indication (RA), TNF- $\alpha$  plays a central role in the pathogenesis of IBD, as evidenced by the efficacy of approved TNF- $\alpha$  inhibitors in the treatment of UC and/or CD. In addition to the binding and neutralization of sTNF $\alpha$ , the efficacy of adalimumab in the treatment of IBD is thought to also involve reverse signaling via binding to tmTNF- $\alpha$ , and other plausible mechanisms of action involving the Fc region of the antibody<sup>7,8,9</sup>. The mechanisms by which adalimumab exerts its therapeutic effect are expected to be the same in adults vs. pediatric CD and pediatric UC patients. Together with demonstrated structural and functional similarity between PF-06410293 and US-Humira, the mechanisms of action of PF-06410293 are not expected to be different from that of US-Humira in pediatric CD and pediatric UC patients, to the extent that the mechanisms are known or can be reasonably determined.

**Pharmacokinetics (PK)-** There are no significant differences in the PK characteristics of US-Humira in healthy subjects or across its various approved indications. Adalimumab concentrations are similar in adult vs. pediatric CD and UC patients (Humira USPI, 2021). Together with the data from the original BLA that demonstrated a 3-way PK similarity between PF-06410293 vs. US-Humira vs. EU-Humira in healthy volunteers (Study B5381007), and between PF-06410293 vs. EU-Humira in patients with RA (Study B5381002), the PK following PF-06410293 are not expected to be different to that of US-Humira in pediatric CD and pediatric UC patients.

**Immunogenicity-** There is no scientific data or evidence to assume that the mechanisms involved in the development of ADAs would differ across indications to preclude extrapolation of immunogenicity data. Immunogenicity rates of US-Humira are comparable between adult vs. pediatric CD and UC patients (Humira USPI, 2021). Together with the comparable immunogenicity in healthy volunteers (PF-06410293 vs. US-Humira vs. EU-Humira, in Study B5381007) and in RA patients (PF-06410293 vs. EU-Humira, in B5381002), the immunogenicity of PF-06410293 is not expected to be different from that of US-Humira in pediatric CD and UC patients.

**Safety-** The safety profile of US-Humira was comparable in adult vs. pediatric CD and pediatric UC patients (Humira USPI, 2021). Together with the data submitted to the original BLA that demonstrated comparable safety profile of PF-06410293 vs. EU-Humira in adult RA patients, combined with establishment of an adequate scientific bridge to justify the relevance of clinical data using EU-Humira as the comparator, the safety of PF-06410293 is not expected to be different from that of US-Humira in pediatric CD and pediatric UC patients.

Note that while the applicant has submitted acceptable extrapolation justification for pediatric UC patients 5 years of age and older, FDA has determined that US-Humira is eligible for orphan drug exclusivity for pediatric UC, ages 5-17 years. FDA therefore cannot license PF-06410293 for this indication prior to the expiration of the orphan drug exclusivity on February 24, 2028.

---

<sup>7</sup> Oikonomopoulos A, et al., Current Drug Targets 2013; 14:1421-32.

<sup>8</sup> Tracey D, et al., Pharmacology & Therapeutics 2008; 117:244-79.

<sup>9</sup> Olesen, C.M, et.al., Pharmacology & Therapeutics 159 (2016), 110-119.

**Regulatory Recommendations:** The Division of Gastroenterology concludes that the totality of the evidence provided by the Applicant supports licensure of PF-06410293 for each of the following indication(s) for which the Applicant is seeking licensure:

the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older.

**Authors:**

**Sandhya K. Apparaju -S**  
Digitally signed by  
Sandhya K. Apparaju -S  
Date: 2022.07.19  
11:34:22 -04'00'

Sandhya Apparaju, PhD  
Clinical Analyst

**Suna Seo -S**  
Digitally signed by  
Suna Seo -S  
Date: 2022.07.19  
12:02:48 -04'00'

Suna Seo, MD, MSc  
Clinical Team Leader

**Juli A. Tomaino -S**  
Digitally signed by  
Juli A. Tomaino -S  
Date: 2022.07.19  
12:26:56 -04'00'

Juli Tomaino, MD, MS  
Deputy Division Director

---

**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**

---

/s/

---

ANIL K RAJPAL

07/21/2022 11:29:50 AM

Signed also for the primary clinical reviewer, Dr. Juwaria Waheed, as she is on extended leave.

NIKOLAY P NIKOLOV

07/21/2022 11:36:05 AM